UK markets closed
NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.06 +0.06 (+0.08%) GOLD FUTURES
2,313.40 +2.40 (+0.10%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,035.27 +1,210.70 (+2.64%)
ALNY Dec 2025 220.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:31AM EDT. Market open.
| Previous close | 19.00 |
| Open | 19.00 |
| Bid | 19.30 |
| Ask | 21.30 |
| Strike | 220.00 |
| Expiry date | 2025-12-19 |
| Day's range | 19.00 - 19.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
ZacksCompared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ZacksAlnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of 78.67% and 17.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
CAMBRIDGE, Mass., May 02, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.
© 2024 Yahoo. All rights reserved.